A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Status:
Withdrawn
Trial end date:
2023-05-11
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of
transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and
effective in participants with cancer that has spread to other parts of the body.